NL301360I2 - talquetamab - Google Patents
talquetamabInfo
- Publication number
- NL301360I2 NL301360I2 NL301360C NL301360C NL301360I2 NL 301360 I2 NL301360 I2 NL 301360I2 NL 301360 C NL301360 C NL 301360C NL 301360 C NL301360 C NL 301360C NL 301360 I2 NL301360 I2 NL 301360I2
- Authority
- NL
- Netherlands
- Prior art keywords
- talquetamab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364811P | 2016-07-20 | 2016-07-20 | |
| PCT/US2017/042982 WO2018017786A2 (en) | 2016-07-20 | 2017-07-20 | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL301360I2 true NL301360I2 (nl) | 2026-02-10 |
Family
ID=60992891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301360C NL301360I2 (nl) | 2016-07-20 | 2026-01-14 | talquetamab |
Country Status (41)
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| TN2018000266A1 (en) | 2016-02-03 | 2020-01-16 | Amgen Res Munich Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs. |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| WO2018035710A1 (en) * | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| WO2018147245A1 (ja) * | 2017-02-07 | 2018-08-16 | 第一三共株式会社 | 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子 |
| KR102845789B1 (ko) | 2017-11-01 | 2025-08-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
| TWI829667B (zh) * | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| WO2019160904A1 (en) | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| CA3100157A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics |
| CN111116753A (zh) * | 2018-10-30 | 2020-05-08 | 上海泰因生物技术有限公司 | 一种双特异性抗体的制备方法 |
| MX2021005024A (es) | 2018-11-01 | 2021-07-21 | Juno Therapeutics Inc | Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b. |
| CA3116413A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| AU2019339582A1 (en) * | 2018-12-04 | 2021-06-17 | Novartis Ag | Binding molecules against CD3 and uses thereof |
| WO2020127618A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic cd28 antigen binding molecules |
| PE20211977A1 (es) * | 2019-01-18 | 2021-10-05 | Janssen Biotech Inc | Receptores de antigenos quimericos de gprc5d y celulas que los expresan |
| TWI905099B (zh) | 2019-05-21 | 2025-11-21 | 瑞士商諾華公司 | Cd19 結合分子及其用途 |
| SG11202111943UA (en) | 2019-07-02 | 2021-11-29 | Hutchinson Fred Cancer Res | Recombinant ad35 vectors and related gene therapy improvements |
| SG11202112491WA (en) * | 2019-07-31 | 2021-12-30 | Hoffmann La Roche | Antibodies binding to gprc5d |
| WO2021018925A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
| CN115335399A (zh) * | 2019-12-06 | 2022-11-11 | 朱诺治疗学股份有限公司 | 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法 |
| IL296514A (en) | 2020-03-30 | 2022-11-01 | Univ Mie | Bispecific antibody |
| JP2023535684A (ja) * | 2020-07-17 | 2023-08-21 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体 |
| IL301361A (en) * | 2020-09-16 | 2023-05-01 | Janssen Biotech Inc | Methods for treating multiple myeloma |
| WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
| CN116789824A (zh) * | 2021-01-05 | 2023-09-22 | 上海礼新医药研发有限公司 | 抗gprc5d单克隆抗体及其用途 |
| SI4284512T1 (sl) | 2021-01-28 | 2025-06-30 | Regeneron Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje sindroma sproščanja citokinov |
| PE20241170A1 (es) | 2021-02-16 | 2024-05-28 | Janssen Pharmaceutica Nv | Anticuerpo triespecifico dirigido a bcma, gprc5d, y cd3 |
| TWI830151B (zh) * | 2021-02-19 | 2024-01-21 | 大陸商信達生物製藥（蘇州）有限公司 | 抗GPRC5DxBCMAxCD3三特異性抗體及其用途 |
| BR112023019484A2 (pt) | 2021-03-24 | 2023-12-05 | Janssen Biotech Inc | Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3 |
| TW202309522A (zh) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物 |
| WO2022247804A1 (zh) * | 2021-05-23 | 2022-12-01 | 上海祥耀生物科技有限责任公司 | 抗gprc5d抗体、其制备方法与用途 |
| WO2023030272A1 (zh) * | 2021-08-30 | 2023-03-09 | 原启生物科技(上海)有限责任公司 | 抗gprc5d抗原结合蛋白及其用途 |
| JP2024540304A (ja) | 2021-11-03 | 2024-10-31 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少 |
| CN118159565A (zh) * | 2021-11-05 | 2024-06-07 | 正大天晴药业集团股份有限公司 | 结合gprc5d的抗体及其用途 |
| AU2022418639A1 (en) | 2021-12-21 | 2024-08-01 | Shanghai Iaso Biotechnology Co., Ltd. | Fully human antibody targeting gprc5d and chimeric antigen receptor (car) and use thereof |
| WO2023115347A1 (zh) * | 2021-12-21 | 2023-06-29 | 上海驯鹿生物技术有限公司 | 靶向gprc5d的全人源抗体 |
| WO2023173272A1 (zh) * | 2022-03-15 | 2023-09-21 | 上海驯鹿生物技术有限公司 | 靶向gprc5d的全人源嵌合抗原受体(car)及其应用 |
| WO2023125888A1 (zh) * | 2021-12-31 | 2023-07-06 | 山东先声生物制药有限公司 | 一种gprc5d抗体及其应用 |
| CA3244652A1 (en) * | 2021-12-31 | 2025-05-22 | Kyinno Biotechnology Co., Ltd. | Anti-GPRC5D Antibodies and Their Use |
| CN116375868A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| EP4464722A4 (en) * | 2022-01-10 | 2026-03-04 | Nanjing Leads Biolabs Co Ltd | ANTIBODIES AND THEIR USE |
| WO2023143537A1 (zh) * | 2022-01-29 | 2023-08-03 | 恺兴生命科技(上海)有限公司 | Gprc5d抗体及其应用 |
| US20250215083A1 (en) * | 2022-03-14 | 2025-07-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| IL317175A (en) * | 2022-05-27 | 2025-01-01 | Antengene Biologics Ltd | Novel anti-GPRC5D antibodies, bispecific antigen-binding molecules that bind GPRC5D and CD3, and uses thereof |
| CA3258254A1 (en) * | 2022-06-06 | 2025-04-07 | Shandong Simcere Biopharmaceutical Co., Ltd. | Multi-specific antibody targeting bcma, gprc5d and t cells and application thereof |
| EP4549466A1 (en) * | 2022-06-30 | 2025-05-07 | Keymed Biosciences (Chengdu) Co., Ltd. | Development and use of novel multispecific tumor inhibitor |
| CN119698434A (zh) * | 2022-07-21 | 2025-03-25 | 山东先声生物制药有限公司 | 抗gprc5d纳米抗体及其应用 |
| KR20250047766A (ko) | 2022-08-05 | 2025-04-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d 및 bcma에 특이적인 키메라 항원 수용체 |
| CN116003598B (zh) * | 2022-08-30 | 2024-04-26 | 苏州缔码生物科技有限公司 | 靶向人gprc5d的重组人源化单克隆抗体及其应用 |
| JP2025529210A (ja) | 2022-09-01 | 2025-09-04 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法 |
| JP2025532460A (ja) * | 2022-09-09 | 2025-10-01 | ベイジン マブワークス バイオテック カンパニー リミテッド | 多重特異性抗体結合ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３、及びその使用 |
| TW202423969A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法 |
| TW202423970A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法 |
| TW202430211A (zh) | 2022-10-10 | 2024-08-01 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法 |
| CN117924485A (zh) * | 2022-10-25 | 2024-04-26 | 上海祥耀生物科技有限责任公司 | 一种抗gprc5d的多特异性抗体 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN120456931A (zh) * | 2022-12-22 | 2025-08-08 | 詹森药业有限公司 | 制备抗体-多核苷酸缀合物的方法 |
| TW202434644A (zh) | 2023-02-07 | 2024-09-01 | 大陸商上海齊魯製藥研究中心有限公司 | 三特異性抗原結合分子及其應用 |
| IL322545A (en) | 2023-02-17 | 2025-10-01 | Regeneron Pharma | Induced NK cells responding to bispecific CD3/TAA antibodies |
| CN120916780A (zh) | 2023-02-28 | 2025-11-07 | 詹森生物科技公司 | 包含双特异性gprc5d/cd3抗体的组合物 |
| CN120882747A (zh) * | 2023-03-22 | 2025-10-31 | 百放英库医药科技(北京)有限公司 | 一种抗gprc5d纳米抗体及其应用 |
| EP4703384A1 (en) * | 2023-04-28 | 2026-03-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bispecific antibody targeting g protein-coupled receptor |
| EP4714974A1 (en) * | 2023-05-16 | 2026-03-25 | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. | Bispecific antigen binding molecule and use thereof |
| KR20260020402A (ko) | 2023-06-01 | 2026-02-11 | 얀센 바이오테크 인코포레이티드 | 다발성 골수종의 치료 방법 |
| WO2024251154A1 (zh) | 2023-06-06 | 2024-12-12 | 信达生物制药(苏州)有限公司 | 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途 |
| KR20260021753A (ko) * | 2023-06-09 | 2026-02-13 | 안텐진 바이올로직스 리미티드 | Cd3 및 다른 표적을 표적화하는 신규 항체 및 이의 용도 |
| CN121311505A (zh) * | 2023-06-28 | 2026-01-09 | 浙江博锐生物制药有限公司 | 抗gprc5d抗体及其医药用途 |
| CN121586730A (zh) * | 2023-07-20 | 2026-02-27 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| TW202527983A (zh) * | 2023-09-13 | 2025-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種包含特異性結合ｇｐｒｃ５ｄ和ｃｄ３的雙特異性抗體的醫藥組成物 |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025094085A1 (en) | 2023-10-31 | 2025-05-08 | Janssen Biotech, Inc. | Combination regimens for treating multiple myeloma |
| TW202542185A (zh) * | 2023-12-08 | 2025-11-01 | 美商健生生物科技公司 | 具有增強的效應功能之ｇｐｒｃ５ｄ抗體及其用途 |
| WO2025134050A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| WO2025134049A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| CN117843788B (zh) * | 2024-01-09 | 2025-02-11 | 四川大学 | 一种抗gprc5d的抗体及其多特异性抗体和相关应用 |
| CN118108846B (zh) * | 2024-02-04 | 2024-11-26 | 四川大学华西医院 | 靶向GPRC5D同种异体CAR-γδT细胞的制备及应用 |
| WO2025194478A1 (en) * | 2024-03-22 | 2025-09-25 | Biofront Ltd | Antibodies binding to cd3 and gprc5d, and uses thereof |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025259877A1 (en) * | 2024-06-12 | 2025-12-18 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting gprc5d and cd3 and methods of use thereof |
| WO2026001931A1 (zh) * | 2024-06-24 | 2026-01-02 | 南京蓬勃生物科技有限公司 | Gprc5d结合分子及其用途 |
| WO2026015729A1 (en) | 2024-07-11 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | Gprc5d x cd28 bispecific antibodies and methods of use thereof |
| US12545726B1 (en) | 2025-07-22 | 2026-02-10 | Integral Molecular, Inc. | Compositions and methods related to GPRC5D binding agents and variants thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU4347701A (en) | 2000-03-01 | 2001-09-12 | Corixa Corp | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| EP1468694A1 (en) * | 2001-12-27 | 2004-10-20 | Sumitomo Pharmaceuticals Company, Limited | Remedies for anorexia or lifestyle-related diseases and method of screening the same |
| WO2005086568A2 (en) * | 2004-01-26 | 2005-09-22 | Morphosys Ag | Anti-icam-1 human antibodies and uses thereof |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| AU2006317242A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos |
| AU2009248049B2 (en) * | 2008-05-16 | 2015-07-23 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| EP3106468A1 (en) | 2008-10-01 | 2016-12-21 | Amgen Research (Munich) GmbH | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| AU2009299793B2 (en) | 2008-10-01 | 2016-03-10 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| BRPI0919881B1 (pt) | 2008-10-31 | 2021-09-08 | Centocor Ortho Biotech Inc | Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação |
| BRPI1008532B1 (pt) | 2009-02-12 | 2021-12-14 | Janssen Biotech, Inc | Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AU2012332021B8 (en) | 2011-11-04 | 2017-10-12 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| FR2994803B1 (fr) | 2012-08-30 | 2016-02-26 | Oreal | Modulation de la forme des fibres keratiniques |
| UA119320C2 (uk) | 2013-02-26 | 2019-06-10 | Рош Глікарт Аг | Активуюча т-клітини біспецифічна антигензв'язувальна молекула |
| KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| JO3568B1 (ar) * | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | عوامل ربط cd123 واستخداماتها |
| EP3191187B1 (en) | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| KR20230159637A (ko) * | 2014-12-05 | 2023-11-21 | 메모리얼 슬로안 케터링 캔서 센터 | G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법 |
| NZ777133A (en) | 2015-06-22 | 2025-05-02 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| TWI811023B (zh) | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| MA43164A (fr) | 2015-11-02 | 2018-09-12 | Janssen Pharmaceutica Nv | Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| WO2018147245A1 (ja) | 2017-02-07 | 2018-08-16 | 第一三共株式会社 | 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子 |
| US11970542B2 (en) | 2017-11-08 | 2024-04-30 | Fred Hutchinson Cancer Center | Bispecific antibodies specific for treating hematological malignancies |
| IL301361A (en) | 2020-09-16 | 2023-05-01 | Janssen Biotech Inc | Methods for treating multiple myeloma |
| TW202309522A (zh) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物 |
-
2017
- 2017-07-18 TW TW106123980A patent/TWI781108B/zh active
- 2017-07-19 UY UY0001040672A patent/UY40672A/es active IP Right Grant
- 2017-07-19 UY UY0001040769A patent/UY40769A/es active IP Right Grant
- 2017-07-19 UY UY0001040770A patent/UY40770A/es not_active Application Discontinuation
- 2017-07-19 UY UY0001040768A patent/UY40768A/es unknown
- 2017-07-19 AR ARP170102018A patent/AR109499A1/es active IP Right Grant
- 2017-07-19 UY UY0001037340A patent/UY37340A/es active IP Right Grant
- 2017-07-20 SI SI201731627T patent/SI3487882T1/sl unknown
- 2017-07-20 PE PE2024000391A patent/PE20240884A1/es unknown
- 2017-07-20 CR CR20190025A patent/CR20190025A/es unknown
- 2017-07-20 CN CN201780057838.6A patent/CN109715667B/zh active Active
- 2017-07-20 IN IN201917002488A patent/IN201917002488A/en unknown
- 2017-07-20 HR HRP20251181TT patent/HRP20251181T1/hr unknown
- 2017-07-20 AU AU2017299673A patent/AU2017299673B2/en active Active
- 2017-07-20 US US15/655,086 patent/US10562968B2/en active Active
- 2017-07-20 KR KR1020197004695A patent/KR102572091B1/ko active Active
- 2017-07-20 BR BR112019001055-6A patent/BR112019001055A2/pt active Search and Examination
- 2017-07-20 HU HUE17745951A patent/HUE073077T2/hu unknown
- 2017-07-20 KR KR1020237028767A patent/KR102811945B1/ko active Active
- 2017-07-20 KR KR1020257016487A patent/KR20250073578A/ko active Pending
- 2017-07-20 IL IL264334A patent/IL264334B2/en unknown
- 2017-07-20 WO PCT/US2017/042982 patent/WO2018017786A2/en not_active Ceased
- 2017-07-20 SG SG11201900468YA patent/SG11201900468YA/en unknown
- 2017-07-20 EP EP25189388.9A patent/EP4643953A2/en active Pending
- 2017-07-20 SM SM20250356T patent/SMT202500356T1/it unknown
- 2017-07-20 NZ NZ790480A patent/NZ790480A/en unknown
- 2017-07-20 PE PE2019000228A patent/PE20190392A1/es unknown
- 2017-07-20 EP EP17745951.8A patent/EP3487882B1/en active Active
- 2017-07-20 IL IL298277A patent/IL298277A/en unknown
- 2017-07-20 JP JP2019502647A patent/JP7292200B2/ja active Active
- 2017-07-20 DK DK17745951.8T patent/DK3487882T3/da active
- 2017-07-20 LT LTEPPCT/US2017/042982T patent/LT3487882T/lt unknown
- 2017-07-20 ES ES17745951T patent/ES3042078T3/es active Active
- 2017-07-20 NZ NZ750152A patent/NZ750152A/en unknown
- 2017-07-20 CN CN202211621205.2A patent/CN116333133A/zh active Pending
- 2017-07-20 MX MX2019000825A patent/MX2019000825A/es unknown
- 2017-07-20 FI FIEP17745951.8T patent/FI3487882T3/fi active
- 2017-07-20 RS RS20250945A patent/RS67235B1/sr unknown
- 2017-07-20 CA CA3031472A patent/CA3031472A1/en active Pending
- 2017-07-20 MA MA45712A patent/MA45712B1/fr unknown
- 2017-07-20 EA EA201990346A patent/EA201990346A1/ru unknown
- 2017-07-20 PL PL17745951.8T patent/PL3487882T3/pl unknown
- 2017-07-20 PT PT177459518T patent/PT3487882T/pt unknown
-
2019
- 2019-01-18 CL CL2019000146A patent/CL2019000146A1/es unknown
- 2019-01-18 MX MX2024001615A patent/MX2024001615A/es unknown
- 2019-01-18 NI NI201900005A patent/NI201900005A/es unknown
- 2019-01-18 MX MX2023006449A patent/MX2023006449A/es unknown
- 2019-01-21 PH PH12019500152A patent/PH12019500152A1/en unknown
- 2019-02-05 CO CONC2019/0001114A patent/CO2019001114A2/es unknown
- 2019-02-19 EC ECSENADI201912075A patent/ECSP19012075A/es unknown
- 2019-02-19 ZA ZA2019/01066A patent/ZA201901066B/en unknown
-
2020
- 2020-02-03 US US16/779,713 patent/US11685777B2/en active Active
-
2022
- 2022-10-28 JP JP2022173361A patent/JP7469432B2/ja active Active
-
2023
- 2023-01-20 US US18/157,800 patent/US11884722B2/en active Active
- 2023-12-04 US US18/528,157 patent/US20240343796A1/en active Pending
-
2024
- 2024-01-31 JP JP2024013728A patent/JP2024054176A/ja active Pending
- 2024-02-14 CL CL2024000444A patent/CL2024000444A1/es unknown
- 2024-03-08 AR ARP240100592A patent/AR132097A2/es unknown
- 2024-04-04 CL CL2024001015A patent/CL2024001015A1/es unknown
- 2024-04-04 CL CL2024001016A patent/CL2024001016A1/es unknown
- 2024-07-22 AU AU2024205021A patent/AU2024205021A1/en active Pending
- 2024-09-13 AR ARP240102459A patent/AR133827A2/es unknown
- 2024-09-13 AR ARP240102458A patent/AR133826A2/es unknown
-
2026
- 2026-01-12 LT LTPA2026501C patent/LTPA2026501I1/lt unknown
- 2026-01-12 FI FIC20265003C patent/FIC20265003I1/fi unknown
- 2026-01-12 NO NO2026001C patent/NO2026001I1/no unknown
- 2026-01-13 FR FR26C1002C patent/FR26C1002I1/fr active Active
- 2026-01-14 NL NL301360C patent/NL301360I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20265003I1 (fi) | Talketamabi | |
| EP3502950A4 (en) | MULTIPLIER-ACC | |
| DK3405050T3 (da) | Børnesikret snusbeholder | |
| EP3440949A4 (en) | FLAVOR INHALER | |
| EP3446605A4 (en) | HAND VACUUM | |
| DK3436823T3 (da) | Antigen-array | |
| EP3455498A4 (en) | Fuel delivery injector | |
| EP3450133A4 (en) | Liquid blow molding method | |
| DK3335532T3 (da) | Tandharve | |
| DK3402792T3 (da) | Quinolin-2-on-derivater | |
| EP3402022A4 (en) | GRAB WIRE | |
| EP3465295A4 (en) | STACK OF POLARIZERS | |
| DK3445708T3 (da) | Stigbøjle | |
| EP3484035A4 (en) | HYSTERESIS SUPPLY CIRCUIT | |
| EP3402021A4 (en) | GRAB WIRE | |
| DK3452590T3 (da) | Plademagnet | |
| DK3509963T3 (da) | Pallecontainer | |
| EP3475155A4 (en) | WING SAILING BOAT | |
| DK3528829T3 (da) | Bacitracin-alginat-oligomer-konjugater | |
| DK3575238T3 (da) | Pallecontainer | |
| EP3399976C0 (en) | BENZOTHIAZOLE AMPHOPHILES | |
| EP3473285A4 (en) | Injector | |
| DE112017000734A5 (de) | Glycolsensor | |
| DE112017006386A5 (de) | Schraubarbeitszylinder | |
| DK3323708T3 (da) | Bovfender |